Ra223

DRUG2 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Conditions

Metastatic Hormone-Sensitive Prostate CanceProstate Cancer

Phase 2

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

Not yet recruitingNCT07717099

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDMetastatic Hormone-Sensitive Prostate Cance

Start: 2026-09-01End: 2029-12-01Target: 50Updated: 2026-07-21

Phase 3

Phase III Radium 223 mCRPC-PEACE III

Active, not recruitingNCT02194842

European Organisation for Research and Treatment of Cancer - EORTCProstate Cancer

Start: 2015-10-31End: 2028-12-31Updated: 2025-09-19

Related Papers

PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.

Journal of Clinical Oncology2025-05-281 citations

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.

2025-03-014 citations

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.

2025-01-1713 citations

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

2025-01-01

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

OPAL (Open@LaTrobe) (La Trobe University)2025-01-01

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations

Abstract 1392: Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model

Cancer Research2021-07-01

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

Journal of Clinical Oncology2021-05-2035 citations

Synergistic antitumor efficacy of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft model.

Journal of Clinical Oncology2021-02-20

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

2020-05-1328 citations

Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.

Journal of Clinical Oncology2019-05-2060 citations

Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).

Journal of Clinical Oncology2018-02-201 citations

Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).

Journal of Clinical Oncology2017-02-204 citations